Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F (2015) Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 21(23), 7281-7288.
Details
PubMed Open Access PDF Paper

Abstract

To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.

Leibniz-HKI-Authors

Selene Mogavero
Selene Mogavero

Details

Identifier

doi: 10.3748/wjg.v21.i23.7281

PMID: 26109816